What is the primary driver of McKesson's revenue growth in this period?

The primary driver of McKesson's revenue growth is its Pharmaceutical Solutions segment, which accounted for over 93% of consolidated revenues and saw a 14% increase in revenue for the quarter.

How did the acquisition of A.L.I. Technologies Inc. and the formation of Verispan impact the company?

The acquisition of A.L.I. Technologies Inc. has been integrated into the Information Solutions segment, complementing its offerings with digital medical imaging solutions. The Verispan joint venture, in which McKesson has a 45% stake, provides patient-level data and healthcare information, impacting the Pharmaceutical Solutions segment.

What were the significant expenses or provisions impacting profitability?

The company recorded a $51 million provision for expected losses on multi-year contracts within its Information Solutions international business. Additionally, restructuring charges were noted in the Medical-Surgical Solutions segment, though some prior year accruals were reversed.

How is McKesson managing its liquidity and financial position?

McKesson is funding its operations through operating cash flow, short-term borrowings, and a significant receivables sales facility. The company's debt-to-capital ratio improved to 22.7%, and it has sufficient credit resources, including revolving credit agreements, to meet future obligations.

MCK 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

McKesson Corporation's Q3 FY2003 report (ending December 31, 2002) shows robust growth, with total revenues increasing by 13% year-over-year for the quarter and 14% for the nine-month period. This growth was primarily driven by the Pharmaceutical Solutions segment, which constitutes over 93% of consolidated revenues. Net income saw a significant increase of 23% for the quarter and 28% for the nine months, reflecting improved operational efficiency and strategic acquisitions. The company has successfully integrated A.L.I. Technologies Inc. and formed the Verispan joint venture, both contributing to its Information Solutions and Pharmaceutical Solutions segments, respectively. Despite facing some contract losses in its international Information Solutions business and ongoing restructuring efforts in Medical-Surgical Solutions, McKesson has demonstrated strong financial performance and improved its liquidity position. The company maintains a healthy debt-to-capital ratio and sufficient credit resources to meet its future obligations.

Key Highlights

1Total revenues increased by 13% to $14.9 billion for the quarter and 14% to $42.2 billion for the nine months ended December 31, 2002.
2Net income grew by 23% to $134.3 million for the quarter and 28% to $376.4 million for the nine months, demonstrating strong profitability.
3The Pharmaceutical Solutions segment continues to be the primary revenue driver, showing a 14% increase in revenues for the quarter.
4Acquisition of A.L.I. Technologies Inc. and formation of the Verispan joint venture are integrating new capabilities and expanding market reach.
5Despite a $51 million provision for contract losses in the international Information Solutions business, overall operating profit increased by 14% for the quarter and 29% for the nine months.
6Cash flow from operations remained strong, providing $357.4 million for the nine-month period.
7The company's debt-to-capital ratio improved to 22.7% as of December 31, 2002, indicating a healthy financial structure.

MCKESSON CORP Quarterly Report for Q3 Ended Dec 31, 2002

Summary

Key Highlights

Frequently Asked Questions